Diagnosing Synucleinopathies: Will Parkinson’s Disease or Dementia with Lewy Bodies Become ‘Biologically’ Defined?

2024/08/13 by Werner Poewe · 1 voice
Medicine · Neuroscience · #Genetic Neurodegenerative Diseases #Neurological disorders and treatments #Parkinson's Disease Mechanisms and Treatments

paper · pdf · doi:10.33590/emjneurol/fdro9946

crossref issued 2024/08/13 · crossref published 2024/08/13 · crossref published-online 2024/08/13 · openalex publication_date 2024/08/13 · crossref created 2024/08/13 · crossref deposited 2024/08/13 · crossref indexed 2024/08/14 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31

Citations

• α-Synuclein in Lewy bodies
• Validation of the MDS clinical diagnostic criteria for Parkinson's disease
• Update of the MDS research criteria for prodromal Parkinson's disease

Discussions

• Disease-modifying trials for #ParkinsonsDisease have faced setbacks. Could a "biological definition" using biomarkers be the key to earlier intervention & better outcomes? Learn about the future of #s [bsky, 1 points, 0 comments]